25.7 C
New York
Thursday, June 4, 2026

Tag: medical

PRINCIPAL TECHNOLOGIES ANNOUNCES PRIVATE PLACEMENT FINANCING AND DEBT SETTLEMENT TRANSACTIONS

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/VANCOUVER, BC, June 3, 2026 /CNW/ - Principal Technologies Inc. (TSXV: PTEC) (FWB:...

Seer Files Definitive Proxy Materials and Mails Letter to Stockholders

Reinforces Seer’s Clear Strategy, Strong Governance and Significant Long-Term Value Creation Opportunity

Booking Health Announces Release of Findings on International Access to Personalized Glioblastoma Treatment in Germany

Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.

Dr. Crystal Nelson Explains How Genetic Testing Is Transforming Mental Health Medication Treatment on YourUpdateTV

New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
New GeneSight ® Mental Health Monitor Reveals 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

Air Products Membrane Solutions Holds Ribbon-Cutting Event for $70 Million Expansion of its Missouri Manufacturing and Logistics Center

The Expansion, which has created more than 70 new positions, is Driven by Growing Interest in the Biogas, Aerospace and Marine Industries Air Products...

Global Manufacturing Market to Reach $968.7 Billion by 2030, Driven by Medical Device and Clean Energy Demand

How AI, robotics, automation, cloud computing and IIoT are accelerating digital transformation across manufacturing and industrial operations.

In HelloNation, Insurance Expert Craig Willoughby of Buffalo, NY, Discusses What’s Included in Homeowners Insurance Policies

BUFFALO, N.Y., June 3, 2026 /PRNewswire/ -- What does homeowners insurance really protect, and how can homeowners avoid costly surprises? That question is answered...

In HelloNation, Holistic Health Expert Cynde Schneider Discusses How Integrative Medicine Differs From Traditional Medical Care

LAMESA, Texas, June 3, 2026 /PRNewswire/ -- The article explores how personalized care and lifestyle-focused evaluations support long-term overall wellness. ...

Medical Grade Physiotherapy & Wellness Now Accepting New Clients in Burlington, Ontario — Redefining One-on-One Rehabilitation & Wellness Care

Burlington, Ontario physiotherapy clinic offering injury rehab, chiropractic care, registered massage therapy, back pain relief, neck pain treatment.

KrystoLens from Brain Navi Receives TFDA Certification, Set to Enter Taiwan Market

Brain Navi Biotechnology Achieves Key Regulatory Milestone Following Recognition at the 22nd National Innovation AwardZHUBEI, June 3, 2026 /PRNewswire/ -- Brain Navi Biotechnology announced that...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial...

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2

New Anglia University: Is Spending Six Years Abroad Still the Best Route Into Medicine?

New Anglia University examines changing medical education pathways, including international medical education and NHS clinical experience.

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedical